DBT

Across TCGA pan-cancer cohorts, DBT Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DBT data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher DBT Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated DBT expression acts as an unfavorable survival marker.

BLCA, ESCA, and UCEC are the cancer types where DBT Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	0.188	0.630	<.001	30	view →
ESCA	OS	Median	All	0.198	0.872	.003	18	view →
UCEC	OS	Median	IV	0.066	0.755	<.001	12	view →
STAD	OS	Median	II,III,IV	0.222	0.710	.005	6	view →
SKCM	DFS	Median	All	0.309	0.734	.004	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DBT–BLCA (DFS)

Open the BLCA breakdown →